昭衍新药董事左从林辞任

财中社
20 Dec 2024

  财中社12月20日电昭衍新药(603127/06127)发布关于董事辞任及补选董事的公告。左从林因个人及工作原因辞去公司董事及副董事长职务,辞职时持有公司A股股份1410万股。该辞职不会影响公司董事会的最低人数要求,也不会影响公司的日常经营管理。

  另外,经公司股东提名、董事会提名委员会资格审核,公司于2024年12月20日召开第四届董事会第十一次会议,同意补选顾静良先生为公司第四届董事会非独立董事候选人,任期自股东大会审议通过之日起至第四届董事会届满之日止。

  2024年前三季度,昭衍新药实现收入13.35亿元,归母净利润-7031万元。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10